Polyglutamine neurodegeneration: protein misfolding revisited

Trends in Neurosciences

Volumn 31, Issue 10, 2008, Pages 521-528

  Williams, Aislinn J ^a,b   Paulson, Henry L ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR;

DISEASE SEVERITY; DRUG EFFICACY; ENZYME DEGRADATION; HOMEOSTASIS; HUMAN; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; POLYGLUTAMINE DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; QUALITY CONTROL; REVIEW;

AGING; ANIMALS; HUMANS; MODELS, BIOLOGICAL; NERVE DEGENERATION; NEUROTOXICITY SYNDROMES; PEPTIDES; PROTEIN FOLDING;

EID: 52049093169     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2008.07.004     Document Type: Review

References (66)

1. Todi S.V., et al. Polyglutamine diseases, including Huntington's disease. In: Waxman S. (Ed). Molecular Neurology. 1st edn (2007), Academic Press 257-275
2. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
3. Rub U., et al. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol. 16 (2006) 218-227
4. Slow E.J., et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11402-11407
5. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95 (1998) 55-66
6. Zoghbi H.Y., and Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23 (2000) 217-247
7. Gatchel J.R., and Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 6 (2005) 743-755
8. Li L.B., et al. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453 (2008) 1107-1111
9. Bennett E.J., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 448 (2007) 704-708
10. Pandey U.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (2007) 859-863
11. Nagai Y., et al. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14 (2007) 332-340
12. Chen S., et al. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41 (2002) 7391-7399
13. Chen S., et al. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11884-11889
14. Li P., et al. The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat. Struct. Mol. Biol. 14 (2007) 381-387
15. Bulone D., et al. The interplay between polyQ and protein context delays aggregation by forming a reservoir of protofibrils. PLoS ONE 1 (2006) e111
16. Klein F.A., et al. Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J. Mol. Biol. 371 (2007) 235-244
17. Marchut A.J., and Hall C.K. Side-chain interactions determine amyloid formation by model polyglutamine peptides in molecular dynamics simulations. Biophys. J. 90 (2006) 4574-4584
18. Takahashi T., et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17 (2008) 345-356
19. Li M., et al. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J. Biol. Chem. 282 (2007) 3157-3164
20. Weiss A., et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J. Neurochem. 104 (2008) 846-858
21. Butland S.L., et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 8 (2007) 126
22. Lim J., et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452 (2008) 713-718
23. Lam Y.C., et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127 (2006) 1335-1347
24. Friedman M.J., et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 10 (2007) 1519-1528
25. Schaffar G., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15 (2004) 95-105
26. Palhan V.B., et al. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8472-8477
27. Helmlinger D., et al. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 4 (2006) e67
28. Zhang S., et al. Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 108 (2002) 45-56
29. Kaltenbach L.S., et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3 (2007) e82
30. Muchowski P.J., and Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 6 (2005) 11-22
31. Nollen E.A., et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6403-6408
32. Tagawa K., et al. The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J. Neurosci. 27 (2007) 868-880
33. Bilen J., and Bonini N.M. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet. 3 (2007) 1950-1964
34. Branco J., et al. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum. Mol. Genet. 17 (2008) 376-390
35. Melville M.W., et al. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol. Cell. Biol. 23 (2003) 3141-3151
36. Kitamura A., et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat. Cell Biol. 8 (2006) 1163-1170
37. Tam S., et al. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat. Cell Biol. 8 (2006) 1155-1162
38. Behrends C., et al. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol. Cell 23 (2006) 887-897
39. Gidalevitz T., et al. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311 (2006) 1471-1474
40. Miller V.M., et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 25 (2005) 9152-9161
41. Jana N.R., et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280 (2005) 11635-11640
42. Shin Y., et al. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280 (2005) 23727-23734
43. Dickey C.A., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 26 (2006) 6985-6996
44. Choi J.Y., et al. Co-chaperone CHIP promotes aggregation of ataxin-1. Mol. Cell. Neurosci. 34 (2007) 69-79
45. Al-Ramahi I., et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 281 (2006) 26714-26724
46. Kumar P., et al. CHIP and HSPs interact with β-APP in a proteasome-dependent manner and influence Aβ metabolism. Hum. Mol. Genet. 16 (2007) 848-864
47. Adachi H., et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 27 (2007) 5115-5126
48. Tsai Y.C., et al. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278 (2003) 22044-22055
49. Matsumoto M., et al. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J. 23 (2004) 659-669
50. Mishra A., et al. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J. Biol. Chem. 283 (2008) 7648-7656
51. Cummings C.J., et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24 (1999) 879-892
52. Ellisdon A.M., et al. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J. Mol. Biol. 368 (2007) 595-605
53. Diaz-Hernandez M., et al. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J. Neurosci. 25 (2005) 9773-9781
54. Walsh D.M., and Selkoe D.J. Aβ oligomers - a decade of discovery. J. Neurochem. 101 (2007) 1172-1184
55. Lesné S., et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
56. Shankar G.M., et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008) 837-842
57. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
58. Kayed R., et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2 (2007) 18
59. Cohen E., et al. Opposing activities protect against age-onset proteotoxicity. Science 313 (2006) 1604-1610
60. Hsu A.L., et al. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300 (2003) 1142-1145
61. Morley J.F., et al. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10417-10422
62. Balch W.E., et al. Adapting proteostasis for disease intervention. Science 319 (2008) 916-919
63. Waza M., et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11 (2005) 1088-1095
64. Brignull H.R., et al. Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J. Neurosci. 26 (2006) 7597-7606
65. Boeddrich A., et al. An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J. 25 (2006) 1547-1558
66. Jia K., et al. Autophagy genes protect against disease caused by polyglutamine expansion proteins in Caenorhabditis elegans. Autophagy 3 (2007) 21-25